Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
YM158 for LTD4 and TXA2 receptors are exhibited at the same dose range
and prevents DMBA-induced inhibition of cell growth
InChi: InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5
Valencene inhibits the exaggerated expression of Th2 chemokines and proinflammatory chemokines through blockade of the NF-κB pathway
Smiles: C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)CCCC
PF-06835919 Catalog No.:M33609-C YM158 for LTD4 and TXA2PF 06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF 06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to
US$ 77.95
US$ 147.50
US$ 87.50
US$ 2125.00
US$ 22.00
US$ 1125.00
US$ 120.00
US$ 1475.00
US$ 127.50
US$ 2725.00
US$ 1575.00